Nutritional safety and status following a 12‐week strict low FODMAP diet in patients with irritable bowel syndrome

Eline Margrete Randulff Hillestad, Elisabeth Kjelsvik Steinsvik, Erica Sande Teige, Stella Hellgren Rasmussen, Ingeborg Brønstad, Arvid Lundervold, Trygve Hausken, Kurt Hanevik, Gülen Arslan Lied, Birgitte Berentsen
{"title":"Nutritional safety and status following a 12‐week strict low FODMAP diet in patients with irritable bowel syndrome","authors":"Eline Margrete Randulff Hillestad, Elisabeth Kjelsvik Steinsvik, Erica Sande Teige, Stella Hellgren Rasmussen, Ingeborg Brønstad, Arvid Lundervold, Trygve Hausken, Kurt Hanevik, Gülen Arslan Lied, Birgitte Berentsen","doi":"10.1111/nmo.14814","DOIUrl":null,"url":null,"abstract":"BackgroundA low FODMAP diet (LFD) is an established dietary treatment for patients with irritable bowel syndrome (IBS). However, knowledge on the extended effects of the restriction phase regarding nutrient intake, symptom severity, and quality of life (QoL) is sparse. Therefore, our objectives were to evaluate the safety of a dietitian‐led 12‐week strict LFD on measures of blood biochemistry, nutritional status, symptom severity, and QoL.MethodsIn this open‐label dietitian‐led 12‐week strict LFD intervention for IBS patients with predominantly diarrhea or mixed stool pattern (IBS‐D/−M), we collected data on diet intake (3‐day dietary record), overnight fasting routine blood samples, body weight, IBS symptoms (IBS Severity Scoring System (IBS‐SSS)), and IBS‐related QoL (IBS‐QoL) at baseline and after 12 weeks.Key ResultsThirty‐six participants completed the 12‐week follow‐up (mean age: 37 years, 67% women, IBS‐SSS: 242 (101)). All blood parameters measured were within established reference values at both time points. We found no change in intake of macro‐ or micronutrients, but several micronutrients were below the recommendations both before and after 12 weeks. BMI slightly decreased, primarily driven by participants with BMI &gt;25 (<jats:italic>p</jats:italic> &lt; 0.005). QoL improved among most subdomains (<jats:italic>p</jats:italic> ≤ 0.002), except <jats:italic>food avoidance</jats:italic> and <jats:italic>social reaction.</jats:italic>ConclusionAn extended dietitian‐guided LFD (12 weeks) is not inferior to the participants' baseline diet, since no clinically meaningful changes in nutritionally related blood samples and no changes in macro‐ or micronutrient intake were observed. However, the intake of several nutrients was below the recommendations at both time points indicating low diet quality.","PeriodicalId":19104,"journal":{"name":"Neurogastroenterology & Motility","volume":"27 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurogastroenterology & Motility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/nmo.14814","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundA low FODMAP diet (LFD) is an established dietary treatment for patients with irritable bowel syndrome (IBS). However, knowledge on the extended effects of the restriction phase regarding nutrient intake, symptom severity, and quality of life (QoL) is sparse. Therefore, our objectives were to evaluate the safety of a dietitian‐led 12‐week strict LFD on measures of blood biochemistry, nutritional status, symptom severity, and QoL.MethodsIn this open‐label dietitian‐led 12‐week strict LFD intervention for IBS patients with predominantly diarrhea or mixed stool pattern (IBS‐D/−M), we collected data on diet intake (3‐day dietary record), overnight fasting routine blood samples, body weight, IBS symptoms (IBS Severity Scoring System (IBS‐SSS)), and IBS‐related QoL (IBS‐QoL) at baseline and after 12 weeks.Key ResultsThirty‐six participants completed the 12‐week follow‐up (mean age: 37 years, 67% women, IBS‐SSS: 242 (101)). All blood parameters measured were within established reference values at both time points. We found no change in intake of macro‐ or micronutrients, but several micronutrients were below the recommendations both before and after 12 weeks. BMI slightly decreased, primarily driven by participants with BMI >25 (p < 0.005). QoL improved among most subdomains (p ≤ 0.002), except food avoidance and social reaction.ConclusionAn extended dietitian‐guided LFD (12 weeks) is not inferior to the participants' baseline diet, since no clinically meaningful changes in nutritionally related blood samples and no changes in macro‐ or micronutrient intake were observed. However, the intake of several nutrients was below the recommendations at both time points indicating low diet quality.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠易激综合征患者接受为期 12 周的严格低 FODMAP 饮食后的营养安全性和状况
背景低 FODMAP 饮食(LFD)是治疗肠易激综合征(IBS)患者的成熟饮食疗法。然而,有关限制阶段对营养摄入、症状严重程度和生活质量(QoL)的扩展影响的知识却很少。因此,我们的目标是评估由营养师指导的为期 12 周的严格低脂饮食对血液生化指标、营养状况、症状严重程度和 QoL 的安全性。方法 在这项针对以腹泻或混合便为主的肠易激综合征患者(IBS-D/-M)的开放标签营养师主导的 12 周严格低脂饮食干预中,我们收集了基线和 12 周后的饮食摄入量(3 天饮食记录)、隔夜空腹血常规样本、体重、肠易激综合征症状(肠易激综合征严重程度评分系统(IBS-SSS))和肠易激综合征相关 QoL(IBS-QoL)数据。主要结果36名参与者完成了为期12周的随访(平均年龄:37岁,67%为女性,IBS-SSS:242(101))。在两个时间点测量的所有血液参数均在既定参考值范围内。我们发现宏观或微量营养素的摄入量没有变化,但有几种微量营养素的摄入量在 12 周前和 12 周后都低于推荐值。体重指数略有下降,主要是体重指数为 25 的参与者(p <0.005)。结论:营养师指导的长效低脂饮食(12 周)并不比参与者的基线饮食差,因为没有观察到与营养相关的血液样本发生有临床意义的变化,也没有观察到宏量或微量营养素摄入量的变化。不过,在两个时间点,几种营养素的摄入量均低于建议值,这表明饮食质量较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Normative high resolution esophageal manometry values in asymptomatic patients with obesity A systematic review of yoga for the treatment of gastrointestinal disorders Characterization of idiopathic chronic diarrhea and associated intestinal inflammation and preliminary observations of effects of vagal nerve stimulation in a non‐human primate Sacral neuromodulation in children and adolescents with defecation disorders Real‐world outcomes for a digital prescription mobile application for adults with irritable bowel syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1